Thermo Fisher Scientific Opens New GMP-certified Ultra-cold Facility in the EU to Accelerate Advanced Therapies Development
3.6.2024 09:00:00 EEST | Business Wire | Press release
Thermo Fisher Scientific Inc., the world leader in serving science, has opened a new clinical and commercial ultra-cold facility in the EU, expanding its clinical trial network in Europe to help accelerate the development of advanced therapies. The new current good manufacturing practice (cGMP) facility in Bleiswijk, Netherlands provides pharma and biopharma customers tailored, end-to-end support throughout the clinical supply chain for high-value therapies, including cell and gene therapies, biologics, antibodies and vaccines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240602205471/en/
Thermo Fisher Scientific announces the opening of a new site in the Netherlands specializing in ambient to cryogenic storage, clinical and commercial packaging, labeling, and distribution, and clinical QP release services (Photo: Business Wire)
To meet increasing demand from cell and gene therapy clinical trials in Europe, this state-of-the-art facility builds on the company’s market leadership and global CDMO capabilities in bioservices and specialty logistics services, including biorepository solutions and critical material storage. The facility enables customers to meet clinical trial requirements regardless of scale or phase by leveraging its highly skilled and talented local workforce to partner with new and emerging biotech and established pharmaceutical companies.
“The opening of this cutting-edge facility supporting the development of cell and gene therapies and other biologics, coupled with our proven track record in managing valuable materials, places us in an unmatched position to help our global clients develop innovative therapies,” said Molly Flick, vice president and general manager, bioservices & specialty logistics, Thermo Fisher Scientific.
The site, 30 minutes outside of Amsterdam, offers clinical and commercial packaging services for cell and gene therapy products from development to commercialization, as well as end to end biorepository storage solutions and associated supply chain services. Capabilities include 5,000-square-meters (54,000 square feet) of ambient to cryogenic storage, ancillaries, and cold chain packaging, labeling, distribution as well as clinical QP release services.
In support of Thermo Fisher’s commitment to sustainability and its global goal of achieving net-zero emissions by 2050, the Bleiswijk site uses 15% solar power and operates completely gas-free, provides sustainable heating and cooling with eco-friendly electric heat pumps, and uses ultramodern heat recovery technology.
Thermo Fisher is dedicated to delivering end-to-end solutions to advance inclusive, impactful clinical research. In addition to the new facility in the EU, Thermo Fisher also recently expanded biologics manufacturing capacity in St. Louis, opened a new cell therapy manufacturing facility in San Francisco, and launched an Innovation Lab in Pennsylvania. To learn more about the company’s capabilities, please visit thermofisher.com/patheon.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602205471/en/
Contact information
Media:
Abbie Martin
Phone: (774) 847-4508
Email: abbie.martin@thermofisher.com
Emily Landers
Phone: (617) 275-6527
Email: elanders@greenoughagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ACE Welcomes Telekom Srbija Group as Newest Member, Expanding Anti-Piracy Fight in Southeast Europe14.7.2026 14:21:00 EEST | Press release
The Alliance for Creativity and Entertainment (ACE), the world’s leading anti-piracy coalition, today announced Telekom Srbija Group as its newest member, strengthening ACE’s content protection efforts in Southeast Europe and across the global digital media ecosystem. Telekom Srbija Group is a leading telecommunications and media group in Southeast Europe, providing connectivity, multimedia and digital services across the region. Operating across 15 markets regionally and globally, and serving more than 14 million users, the Group has established a strong and expanding international footprint. In recent years, the company has expanded beyond its core telecommunications business to become a major investor in premium television, film, sports and digital content, developing its own production and distribution capabilities and licensing its content to international platforms and broadcasters. “Telekom Srbija Group’s decision to join ACE strengthens our collective ability to address digital
STARTEEPO Increases Xerox Position to 8.8 Million Shares, Becomes Second-Largest Common Shareholder14.7.2026 14:00:00 EEST | Press release
STARTEEPO Invest (“STARTEEPO”), a Prague-based alternative investment fund focused on high-conviction public equity investments, today announced that it has increased its beneficial ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”) to 8.8 million common shares, together with options on an additional 140,000 shares, as disclosed in an amended Schedule 13D filing with the U.S. Securities and Exchange Commission. Based on publicly available ownership disclosures, STARTEEPO is now Xerox’s second-largest holder of common stock. “We have reached the target ownership level established for the current phase of our investment strategy,” said Frantisek Bostl, Chairman of the Board of STARTEEPO Invest. STARTEEPO’s investment thesis remains centered on balance sheet improvement, disciplined capital allocation, operational execution, the successful integration of Lexmark, and what we believe is the market’s continued undervaluation of Xerox’s long-term strategic positionin
European Commission Approves Erbitux ® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation14.7.2026 12:00:00 EEST | Press release
Merck, a leading global science and technology company, today announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) — both in first-line treatment in combination with FOLFOX (BREAKWATER regimen) and for patients who have received prior systemic therapy (BEACON regimen). The first-line approval is based on results from the Phase 3 BREAKWATER trial, which showed that the cetuximab–encorafenib–FOLFOX combination delivered statistically significant and clinically meaningful improvements in the dual primary endpoints of objective response rate (ORR) and PFS, as well as a significant overall survival benefit — reducing the risk of death by 51% versus chemotherapy with or without bevacizumab. ”The approval of Erbitux in combination with encorafenib and FOLFOX marks an important milestone for patients wit
Nordic Firms Seek Green, Sovereign AI Infrastructure14.7.2026 12:00:00 EEST | Press release
Nordic enterprises are adopting private and hybrid cloud infrastructure that combines AI-ready capacity, local residency and low-carbon operations as high-performance workloads and geopolitical risk reshape IT strategies, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The 2026 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Nordics finds that the region is evolving from a hosting destination into a backbone for European data processing. Enterprises are using the Nordics’ renewable energy and natural cooling to support cloud strategies that balance large scale with environmental consciousness and compliance with data sovereignty regulations. “Nordic enterprises are connecting infrastructure decisions to resilience, data control and sustainability rather than treating cloud as a capacity purchase,” said Susanta Dey, director, ISG EMEA Cloud and
Swiss Pension Funds Increase Commitments to Record Infrastructure Equity Fund to EUR 1.23 Billion14.7.2026 10:58:00 EEST | Press release
Record Asset Management GmbH (RAM), subsidiary of London-listed Record plc (Record Financial Group), today announced that its Infrastructure Equity fund has attracted EUR 160 million of additional capital from Swiss pension funds, increasing total commitments to approximately EUR 1.23 billion. Capital deployment continues to progress in line with expectations, with more than one-third of the fund’s initial capital now deployed or committed to investments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713541233/en/ RAM manages a dedicated infrastructure co-investment vehicle in partnership with APG, the pension asset manager of ABP, providing Swiss pension funds with access to large-scale infrastructure equity investments alongside APG’s pension fund partners. RAM is the European asset management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom